Guardant Health (GH) recently reported a 48% year over year revenue increase in Q1 2026 and raised full year revenue guidance to US$1.30b to US$1.32b, putting its oncology and screening growth in focus.
See our latest analysis for Guardant Health.
Guardant Health’s recent Q1 update comes after a sharp shift in sentiment, with the stock posting a 90 day share price return of 71.56% and a 1 year total shareholder return of 231.68%, signalling strong momentum despite some short term pullbacks.
If rapid growth in oncology testing has your attention, it could be a good moment to scan the broader healthcare opportunity set and see 41 healthcare AI stocks
After Guardant Health’s sharp share price move and higher full year revenue guidance, the real tension now is clear: pay up today for the momentum, or wait and risk missing the current valuation setup?
Most Popular Narrative: 2.9% Undervalued
The most followed narrative for Guardant Health pegs fair value at $155.25, slightly above the last close of $150.75. This frames the recent rally against a still modest discount.
Substantial regulatory, reimbursement, and clinical validation milestones (including Shield's breakthrough device status, NCCN guideline inclusion, and ongoing pilot studies) are paving the way for further guideline adoption, expanded payer coverage, and commercial inflections in Shield/MCED and Reveal volumes, significantly increasing future revenue and earnings visibility.
Want to see what underpins that fair value call? The narrative focuses on rapid top line expansion, margin repair, and a tiny earnings base supporting a very rich future multiple.
Result: Fair Value of $155.25 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Guardant Health’s story can change quickly if Shield reimbursement or guideline adoption falls short, or if high R&D and SG&A spending keeps losses elevated.
Find out about the key risks to this Guardant Health narrative.
Another View: Guardant Health Through the P/S Lens
The fair value narrative for Guardant Health points to a small 2.9% discount, but the P/S ratio tells a much tougher story. At 18.5x sales versus a fair ratio of 8.7x, and 1.5x for peers and 1.4x for the wider US Healthcare industry, the stock carries a heavy valuation premium that could amplify any future disappointment. Is this price tag simply the cost of a high growth story, or is it a risk that is easy to underestimate?
For a closer look at how this sales based valuation stacks up against peers and where the fair ratio suggests the market could drift over time, See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Guardant Health has clear optimism baked in alongside real concerns, so if this mix of risks and rewards interests you, move quickly, weigh the data yourself, and then check the full breakdown of 2 key rewards and 2 important warning signs
Looking for more Guardant Health style investment ideas?
If Guardant Health has sharpened your focus on high conviction opportunities, do not stop here. Use the Simply Wall St screener to widen your opportunity set today.
- Target resilient income by checking out companies that could support long term payouts through the 7 dividend fortresses.
- Prioritise strength by filtering for businesses with robust finances using the solid balance sheet and fundamentals stocks screener (49 results).
- Unearth future contenders before they attract wider attention with the screener containing 20 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com